Quick Answer
Forte Biosciences, Inc. reported Total Assets of $82.78 million for the year ending 2025.
- Forte Biosciences, Inc. showed an increase of +34.5% in Total Assets from 2024 to 2025.
- This data is from Forte Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $34.29 million | Q2 2017: $110.77 million | Q3 2017: $102.17 million | Q1 2018: $78.74 million | Q2 2018: $87.34 million | Q3 2018: $90.35 million | Q1 2019: $94.73 million | Q2 2019: $85.23 million | Q3 2019: $70.75 million | Q1 2020: $18.63 million | Q2 2020: $28.31 million | Q3 2020: $22.73 million | Q1 2021: $57.07 million | Q2 2021: $52.89 million | Q3 2021: $47.39 million | Q1 2022: $41.30 million | Q2 2022: $39.72 million | Q3 2022: $45.13 million | Q1 2023: $36.71 million | Q2 2023: $31.18 million | Q3 2023: $47.88 million | Q1 2024: $32.02 million | Q2 2024: $26.08 million | Q3 2024: $17.95 million | Q1 2025: $47.46 million | Q2 2025: $107.78 million | Q3 2025: $97.09 million.
- Over the full 10 years of available data (2016 to 2025), Forte Biosciences, Inc.'s Total Assets has grown by 134.2%.
- Historical annual values: Fiscal year 2025: $82.78 million | Fiscal year 2024: $61.56 million | Fiscal year 2023: $38.98 million | Fiscal year 2022: $42.00 million | Fiscal year 2021: $43.31 million | Fiscal year 2020: $61.24 million | Fiscal year 2019: $7.66 million | Fiscal year 2018: $103.08 million | Fiscal year 2017: $92.07 million | Fiscal year 2016: $35.35 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: